PCVs are generally cost-effective compared to no vaccination in HICs and LMICs

Objectives:
What is the incremental net benefit (INB) of the 13-valent PCV (PCV13) and 10-valent PCV (PCV10) in children?

Study design:
This review article included 70 studies.

Results and conclusions:
The investigators found when herd effects were considered, PCV13 was cost-effective compared to PCV10 from the payer perspective in both high-income countries (HICs) [INB = $103.94, 95% CI = $75.28 to $132.60] and low- and middle-income countries (LMICs) [INB = $53.49, 95% CI = $30.42 to $76.55] with statistical significance.
These findings were robust across a series of sensitivity analyses.

The investigators found PCV13 was cost-effective compared to no vaccination across perspectives and consideration of herd effects in both HICs and LMICs, while findings were less consistent for PCV10.

The investigators concluded PCVs are generally cost-effective compared to no vaccination in HICs and LMICs. Furthermore, PCV13 is cost-effective compared to PCV10 when herd effects are considered from the payer perspective in both HICs and LMICs. These findings are sensitive to the consideration of herd effects.

Original title:
Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-effectiveness Studies by Syeed MS, Ghule P, […], Chaiyakunapruk N.

Link:
https://pubmed.ncbi.nlm.nih.gov/36328324/

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition and vaccination right here.